Here we focus on the underlying mechanisms of STAT3 activation in tumor-infiltrating immune cells, which contribute to both innate and adaptive immune suppression, thereby impeding the antitumor efficacy of effector cells. The gene discussed is STAT3; the disease is neoplasm.